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This study investigated the antiobesity effect of an extract of the Fomitopsis pinicola Jeseng-containing formulation (FAVA), which
is a combination of four natural components: Fomitopsis pinicola Jeseng; Acanthopanax senticosus; Viscum album coloratum; and
Allium tuberosum. High-fat diet- (HFD-) fedmale C57BL/6J mice were treated with FAVA (200mg/kg/day) for 12 weeks tomonitor
the antiobesity effect and amelioration of nonalcoholic fatty liver diseases (NAFLD). Body and white adipose tissue (WAT) weights
were reduced in FAVA-treated mice, and a histological examination showed an amelioration of fatty liver in FAVA-treated mice
without decreasing food consumption. Additionally, FAVA reduced serum lipid profiles, leptin, and insulin levels comparedwith the
HFD control group.The FAVA extract suppressed lipogenic mRNA expression levels fromWAT concomitantly with the cholesterol
biosynthesis level in the liver. These results demonstrate the inhibitory effects of FAVA on obesity and NAFLD in the diet-induced
obese (DIO) mouse model. Therefore, FAVAmay be an effective therapeutic candidate for treating obesity and fatty liver caused by
a high-fat diet.
1. Introduction
There is increasing consensus that obesity may be the main
cause of various metabolic disorders. Obesity is caused by
the combined effects of excess energy intake and reduced
energy expenditure. It is one of the fastest growing disorders
worldwide and is associated with various clinical symptoms
in developed countries [1], such as hyperlipidemia, insulin
resistance, and nonalcoholic fatty liver diseases (NAFLD) [2].
It is well known that excessive fat consumption is implicated
in the development of obesity in mice [3], and long-term
feeding with a high-fat diet (HFD) can induce obesity
together with hyperlipidemia, insulin resistance, andNAFLD
[4]. Hyperlipidemia is associated with high levels of lipids
and lipoproteins in the blood and causes atherosclerosis and
acute pancreatitis [5]. AlthoughNAFLD is the second leading
cause of death in the general population [6, 7], there is no
pharmacological agent known to reverse NAFLD. Recently,
effective medical interventions have been focused on the
modification of risk factors, such as diet andweight reduction
[8].
Adipose tissue, an important repository for energy stor-
age, regulates energy homeostasis. Adipogenesis, a differ-
entiation process of adipocytes, involves changes in gene
expression and cellular morphology. Adipocyte hypertrophy
results from an excessive accumulation of lipids from the
intake of inordinate energy sources such as HFD. During
adipogenesis, peroxisome proliferator-activated receptor-𝛾
(PPAR-𝛾) and CCAAT/enhancer-binding protein-𝛼 (C/EBP-
𝛼) play key roles as major transcriptional factors [9]. Expres-
sion of PPAR-𝛾, a transcription factor of the nuclear-receptor
superfamily, and C/EBP-𝛼, a member of the C/EBP family of
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basic leucine zipper class of transcription factors, increases
during 3T3-L1 cell differentiation [10]. Lipin is also a central
regulator of adipose tissue development. Mammalian lipin
proteins have been shown to control gene expression and
to enzymatically convert phosphatidate into diacylglycerol,
an essential precursor in triacylglycerol and phospholipid
synthesis [11]. Previous studies have established that lipin-1
is required at an early step in adipocyte differentiation for
the induction of the adipogenic gene transcription program,
including the key regulator PPAR-𝛾 [12].
Acetoacetyl-CoA synthetase (AACS) regulation is related
to cholesterol and lipid homeostasis [13]. Sterol response
element binding protein-2 (SREBP-2) may play an essential
role in the transcriptional regulation of AACS. SREBP-
2 is a leucine zipper transcription factor that controls a
rate-limiting enzyme in cholesterol synthesis, HMG-CoA
reductase (HMGCR), when the factor binds sterol response
element [14, 15].
The effects ofAcanthopanax senticosus,Allium tuberosum,
andViscum album coloratum have been studied for inhibition
of fatty acid synthase and prevention of obesity, as well
as reducing hepatic steatosis [16–18]. Fomitopsis pinicola
Jeseng has been reported for antihyperglycemic effect in
diabetic rats [19]. In addition, it has been reported that 𝛽-
glucan-rich extract, amajor component of Fomitopsis pinicola
Jeseng, effectively reduces adiposity [19, 20]. However, to our
knowledge, no reports are available on the effect of Fomitopsis
pinicola Jeseng on obesity.
In this study, we investigated the effect of FAVA in a high-
fat diet-induced mouse model.The FAVA is a combination of
herbal extracts (i.e., Fomitopsis pinicola Jeseng,Acanthopanax
senticosus, Allium tuberosum, and Viscum album coloratum)
at a ratio of 5 : 3 : 1 : 1. This study investigated the effect
of a mixture containing dietary components on metabolic
disorders including obesity, hyperlipidemia, and NAFLD
using a high-fat diet-induced obesity mouse model and the
molecular mechanism level of adipogenesis and cholesterol
biosynthesis. Our results indicate the great potential of
FAVA as a potential metabolic regulator of adipogenesis and
cholesterol biosynthesis and as a potential therapeutic agent
for preventing or treating obesity and NAFLD.
2. Materials and Methods
2.1. Preparation of FAVA. The oriental, medicinal, and herbal
mixture used in this experiment (FAVA) was prepared as
described previously [21–23]. Briefly, Acanthopanax sentico-
sus and Allium tuberosumwere extracted with 80%methanol
while water extracted Fomitopsis pinicola Jeseng and Viscum
album coloratum were purchased from commercial vendor
(Mistle Biotech Co., Ltd., Korea). Each extraction of FAVA
was resuspended in distilled water (DW) in a ratio of 50%,
30%, 10%, and 10%, respectively, and prepared in appropriate
diluent for further in vivo study.
2.2. Animals and Diets. Lean, male C57BL/6J mice (7
weeks old) were purchased from Charles River Laboratories
Japan, Inc. (Yokohama, Japan). All animal experiments were
approved by the Ethics Review Committee of the Pohang
Center for the Evaluation of Biomaterials, Republic of Korea.
All mice were housed for 1 week under a 12/12-h light/dark
cycle in a temperature- (22 ± 1∘C) and humidity- (55 ± 5%)
controlled room and fed standard laboratory chow and water
ad libitum while FAVA, orlistat, and saline supplementation
were performed using oral gavage once a day. To induce
obesity, the mice were fed a HFD (Rodent Diet D12492,
Research Diet, New Brunswick, NJ, USA) consisting of
60% kcal fat. Control mice were fed a low-fat chow diet
(Rodent Diet D12450B, Research Diet, New Brunswick, NJ,
USA) consisting of 10% kcal fat. Experimental mice were
given FAVA or orlistat as a positive control (Chongqing Zein
Pharmaceutical Co., Ltd., Chongqing, China).Themice were
randomly divided into four groups (𝑛 = 8 per group) that
were fed a low-fat chow diet (CHOW), a high-fat diet (HFD),
HFD plus FAVA (200mg/kg/day), or HFD plus orlistat
(60mg/kg/day). Animals were fed via oral feeding needles
for 12 weeks, and the CHOW and HFD group received
an equivalent volume of saline. Body weight was measured
once a week, and food intake was measured three times per
week during the course of the study. At the conclusion of
the in vivo experiment, the mice were sacrificed by cervical
vertebral dislocation, and the epididymal, mesenteric, and
subcutaneous fat pads and liver were collected and weighed.
The epididymal fat pad samples were stored at −80∘C until
analysis.
2.3. Serum Analysis. Serum was collected by cardiac punc-
ture, stored for 20 minutes at room temperature for coagu-
lation, and then separated by centrifugation at 2,000×g for
20 minutes. The serum was stored at −70∘C until analysis.
The levels of triglycerides, total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, glucose, alanine transaminase (ALT), aspartate
transaminase (AST), BUN, and creatinine in serum were
measured by using an automated biochemical analyzer (BS-
390, Mindray Bio-Medical Electronics Co., Ltd., China).
2.4. Measurement of Leptin and Insulin. The leptin and
insulin concentrations in serumwere determined by amouse
enzyme-linked immunosorbent assay (ELISA) kit (Morinaga
Institute of Biological Science, Yokohama, Japan).The prepa-
ration of serum samples is described above.
2.5. Abdominal Computed Tomography Analysis. Experi-
ments of micro-computed tomography (micro-CT) were
performed with an animal positron emission tomography
(PET)/CT/single photon emission computed tomography
(SPECT) system (Inveon, Siemens, USA) prior to the sac-
rifice of animals under 1.5–2% isoflurane in O
2
anesthesia.
Computed tomography pictures were further analyzed using
Siemens Inveon software to calculate the three-dimensional
volume of the fat mass between lumbar vertebrae one to five.
2.6. Liver Histology. Liver tissues were immediately isolated
after sacrifice. For hematoxylin and eosin (H&E) staining, the
tissues were fixed in 10% formalin, processed, and embedded
in paraffin prior to sectioning (10 𝜇m) and staining. The liver
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Table 1: Primers used in the reverse transcriptase-polymerase chain reaction analysis.
Gene name Accession number Sequence
Lipin-1 NM 172950 Forward 5
󸀠-TCA GAC ACT TTC AGT AAC TTC AC-3󸀠
Reverse 5󸀠-TAT CAG CCT TCC CAG CAG-3󸀠
C/EBP-𝛼 NM 007678 Forward 5
󸀠-CGT CTA AGA TGA GGG AGT C-3󸀠
Reverse 5󸀠-GGC ACA AGG TTA CTT CCT-3󸀠
PPAR-𝛾 NM 001127330 Forward 5
󸀠-GAA AGA CAA CGG ACA AAT CAC-3󸀠
Reverse 5󸀠-GAA ACT GGC ACC CTT GAA-3󸀠
AACS NM 030210 Forward 5
󸀠-AAG CCC AGA GTT ACG AGT AT-3󸀠
Reverse 5󸀠-ACA CAG GAA TAG AGG AGT TCT-3󸀠
HMGCR NM 008255 Forward 5
󸀠-AGA ATA ATG TGC TAA GTA GTG CTA A-3󸀠
Reverse 5󸀠-GCC TCT CTG AAC AAA GAC TC-3󸀠
SREBP-2 NM 033218 Forward 5
󸀠-GCG ACC AGG AAG AAG AGA-3󸀠
Reverse 5󸀠-ACA AAT CCC ACA GAG TCC A-3󸀠
𝛽-actin NM 007393 Forward 5
󸀠-GGG AAG GTG ACA GCA TTG-3󸀠
Reverse 5󸀠-ATG AAG TAT TAA GGC GGA AGA TT-3󸀠
C/EBP-𝛼: CCAAT/enhancer-binding protein-𝛼; PPAR-𝛾: peroxisome proliferator-activated receptor-𝛾; AACS: acetoacetyl-CoA synthetase; HMGCR: HMG-
CoA reductase; and SREBP-2: sterol regulatory element binding protein-2.
samples of 3 mice from each group (CHOW, HFD, HFD
+ FAVA, and HFD + ORLISTAT) were measured. Briefly,
the following criteria were used for scoring hepatic steatosis:
grade 0 (no fatty liver) and grade 1 (mild fatty liver), if
hepatocytes occupied <33% of the hepatic parenchyma [24].
2.7. RNA Preparation and Real-Time PCR. Total RNA
was extracted by ReliaPrep RNA Tissue Miniprep System
(Promega) according to the manufacturer’s instructions.
RNA integrity was assessed by an automated microfluidics-
based system (Bioanalyzer 2100, Agilent, Palo Alto, CA,
USA). First-strand cDNA was synthesized with the iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA), and real-
time PCR was performed using an iCycler iQ Real-Time
Detection System (Bio-Rad). PCR reactions were conducted
with iQ SYBR Green Supermix (Bio-Rad). Real-time PCR
analysis was performed using an iCycler iQ Real-Time
Detection System (Bio-Rad). Amplification of real-time PCR
was performed according to the protocols of Jung et al. [25].
The reaction was performed at 95∘C for 3min, followed by 39
cycles of amplification (95∘C for 10 s, 58∘C for 10 s, and 72∘C
for 30 s). A melting curve was produced to confirm a single
gene-specific peak and detect primer/dimer formation by
heating the samples from 65 to 95∘C in 0.5∘C increments with
a dwell time at each temperature of 10 s, while continuously
monitoring fluorescence. The mRNA levels of specific genes
were normalized to those of 𝛽-actin. The primers used are
listed in Table 1.
2.8. Statistical Analyses. The data (mean ± SE) were analyzed
using GraphPad Prism (version 5.04, GraphPad Software,
USA). Unpaired two-tailed Student’s 𝑡-tests were used to
evaluate differences betweenmeans as indicated and 𝑝 values
< 0.05 were considered significant.
3. Results
3.1. Effects of FAVA on Body Weight, Dietary Intake, and
Fat Mass in White Adipose Tissue in HFD-Fed Mice. The
effects of FAVA on body weights are shown in Figure 1(a).
During the 12-week experiment, body weight was measured
weekly, and food intake was measured every other day. After
9 weeks, the body weight of the mice in the HFD group
was significantly higher than that of the mice in the CHOW
group (𝑝 < 0.0005). The FAVA-treated group showed a
significant decrease in body weight compared with the HFD
group. At the end of the experiment, the body weight of
the mice fed FAVA was 9.7 ± 2.0% lower (𝑝 < 0.05) than
that of the mice in the HFD group, whereas HF diet plus
orlistat-fed mice weighed almost the same as the mice that
were fed FAVA (Figure 1(a)). These effects of FAVA on body
weight were not due to decreased food intake, because the
amount of kcal consumed per mouse over a 24-h period
remained unchanged (Figure 1(b)). These data indicate that
FAVAmight have antiobesity effects in vivo, without affecting
food intake. To investigate whether body weight loss was
caused by decreased adiposity, the animals were sacrificed,
and the epididymal fat pad, the mesenteric fat pad, and the
subcutaneous fat pad were dissected and weighed. FAVA
supplementation significantly suppressed the increase of fat
mass in all white adipose tissues, including mesenteric, sub-
cutaneous, and epididymal adipose tissue (Figures 1(c)–1(e)).
3.2. Effect of FAVA on Adiposity in HFD-Fed Mice. We
performed micro-CT imaging to assess the effect of FAVA
on adiposity. CT imaging showed a significant reduction in
body fat profiles with FAVA treatment (Figure 2(a)). There
was a significant reduction in fat volume (Figure 2(b)) and
total body fat percentage in FAVA-fed groups compared with
the HFD group (Figures 2(b) and 2(c)).
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Figure 1: Effect of FAVA on body weight, food intake, and white fat pad in mice fed a high-fat diet for 12 weeks. (a) Changes in body weight
gain at each treatment period are shown: (circle) CHOW: chow diet; (black triangle) HFD: high-fat diet; (red triangle) HFD + ORLISTAT:
high-fat diet plus orlistat 60mg/kg; and (green triangle) HFD + FAVA: high-fat diet plus FAVA 200mg/kg. (b) Average food intake expressed
as kcal/mouse/day. ((c)–(e)) Epididymal fat pad (c), mesenteric fat pad (d), and subcutaneous fat pad (e) weights expressed. The values
represent the mean ± standard error of mean (SEM) (#𝑝 < 0.05 and ##𝑝 < 0.005 versus the CHOW group; ∗𝑝 < 0.05, ∗∗𝑝 < 0.005, and
∗∗∗𝑝 < 0.0005 versus the HFD group, 𝑛 = 8 per group).
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Figure 2: Effect of FAVA on high-fat diet-induced adiposity. (a) Micro-computed tomography (micro-CT) pictures were analyzed using
Siemens Inveon software to calculate the three-dimensional volume of the fat mass between vertebrae number one to five of mice fed a chow
diet (CHOW), high-fat diet (HFD),HFDwith 60mg/kg/day orlistat (ORLISTAT), orHFDwith 200mg/kg/day FAVA (FAVA). (b) Fat volumes
(mm3) in mice are shown. (c) Fat pad mass expressed as percentage of total body weight. The values represent the mean ± SEM (#𝑝 < 0.05
versus the CHOW group; ∗𝑝 < 0.05 versus the HFD group, 𝑛 = 3).
3.3. Effects of FAVA on Serum Insulin, Leptin, and Lipid
Profiles in the Serum of HFD-Fed Mice. The changes in the
blood plasma parameters are shown in Figures 3(a)–3(e). As
shown in Figures 3(a) and 3(b), HFD-induced obese mice
showed significantly higher levels of serum insulin and leptin,
whereas the FAVA group showed significantly decreased
levels of serum insulin and leptin by 60.9 ± 8.1% and
40.4 ± 3.0%, respectively. Concomitant reductions of serum
insulin and leptin levels were monitored in the orlistat group
in a similar manner. Additionally, the FAVA group showed
lower levels of serum total cholesterol and the ratio of LDL
cholesterol/total cholesterol than those of the HFD group.
3.4. Effects of FAVA onmRNALevels of Transcriptional Factors
in Epididymal Fat Pad. Because FAVA extract reduced fat
mass in all white adipose tissues and serum insulin levels
(Figures 1 and 3), we evaluated the effect of FAVA on the
expression of various adipogenic and lipogenic genes [26].
PPAR𝛾 and C/EBP𝛼 are known to have roles in insulin
sensitivity, lipogenesis, and lipolysis [27]. Lipin-1 is also
thought to regulate the transcription of genes involved in
adipocyte differentiation and fat synthesis and storage [28].
To investigate the antiadipogenic mechanism, the effects
of FAVA on mRNA expression levels of PPAR𝛾, C/EBP𝛼,
and lipin-1 were determined in the epididymal fat pad. The
expression of both adipogenic genes, PPAR𝛾 and C/EBP𝛼,
was significantly decreased by FAVA (Figures 4(b) and 4(c)).
Additionally, FAVA significantly suppressed lipin-1 expres-
sion by 95.6±0.5% compared with that of theHFD group and
was greater than that of the orlistat group as a positive control.
3.5. Effects of FAVA onHepatic Histology of HFD-Fed C57BL/6
Mice and mRNA Levels of Cholesterol Biosynthesis in Liver.
A common characteristic among people with obesity is
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Figure 3: Effect of FAVA on serum insulin, leptin, and lipid profiles in mice fed a high-fat diet. Changes in insulin (a), leptin (b), total
cholesterol (c), the ratio of HDL cholesterol/total cholesterol (d), and the ratio of LDL cholesterol/total cholesterol (e) of the mice were
measured.The values represent themean ± SEM (#𝑝 < 0.05, ##𝑝 < 0.005, and ###𝑝 < 0.0005 versus the CHOWgroup; ∗𝑝 < 0.05, ∗∗𝑝 < 0.005,
and ∗∗∗𝑝 < 0.0005 versus the HFD group, 𝑛 = 5∼7 per group).
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Figure 4: mRNA expressions of transcription factors in the epididymal fat pad of animals treated with HFD or HFD + ORLISTAT (high-
fat diet plus orlistat 60mg/kg) or FAVA (high-fat diet plus FAVA 200mg/kg) or chow as quantified by real-time PCR. The graphs represent
mRNA expression of transcription factors Lipin-1 (a), ACC and C/EBP-𝛼 (b), and PPAR-𝛾. The data represent the mean ± SEM (#𝑝 < 0.05
and ##𝑝 < 0.005 versus the CHOW group; ∗𝑝 < 0.05 and ∗∗𝑝 < 0.005 versus the HFD group, 𝑛 = 5).
the development of fatty liver [29, 30]. Therefore, we also
analyzed the effect of FAVA on fatty liver development.
Histological evaluation is regarded as the “gold standard”
for assessing the presence and severity of NAFLD [31]. We
histologically evaluated liver sections to determine the extent
to which FAVA attenuated hepatic steatosis development.
As shown in Figure 5(a), mild fatty liver was observed in
mice that were fed a high-fat diet without FAVA. However,
a marked reduction in the degree of steatosis was shown in
livers from high-fat diet mice treated with FAVA. Moreover,
FAVA treatment also decreased total serum cholesterol in
mice to 13.7 ± 3.4% (Figure 3(c)). Therefore, we investigated
whether SREBP-2, AACS, and HMGCR RNA in the mouse
liver were induced by FAVA. Total RNA was prepared from
mouse livers, and SREBP-2, AACS, and HMGCR mRNA
levels were quantified using real-time PCR. SREBP-2, AACS,
and HMGCR mRNA levels were dramatically suppressed in
the mice that were fed FAVA (Figures 5(b) and 5(c)).
4. Discussion
Our study is the first to demonstrate that FAVA prevents
weight gain in HFD-induced obesity in C57Bl/6 mice. Our
results showed that body weight gain in groups fed a
diet supplemented with FAVA was reduced compared with
control HFD mice (Figure 1(a)). Epididymal, mesenteric,
and subcutaneous fat pads in C57BL/6 mice were signif-
icantly reduced by FAVA supplementation (Figures 1(c)–
1(e)). There was a significant reduction in subcutaneous
and abdominal fat mass in FAVA-fed groups compared with
the HFD group (Figures 2(a)–2(c)). Subcutaneous fat and
abdominal fat are the major types of white adipose tissue.
Abdominal obesity is associated with an increased risk of
cardiovascular diseases and insulin resistance [32].This study
also provides evidence that dietary supplementation of FAVA
protects against hepatic steatosis development (Figure 5(a)).
We have considered the possibility that the effect of FAVA
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Figure 5: Effect of FAVA on hepatic steatosis and mRNA expressions of cholesterol biosynthesis in the liver of mice. (a) Hematoxylin and
eosin staining of liver from mice fed chow diet (CHOW), high-fat diet (HFD), or high-fat diet supplemented with orlistat at 60mg/kg/day
(HFD + ORLISTAT) or high-fat diet supplemented with FAVA at 200mg/kg/day (HFD + FAVA) (40x magnification). ((b)–(d)) The graphs
represent mRNA expression of cholesterol synthesis factors AACS (b), HMGCR (c), and SREBP2 (d), which was analyzed by real-time PCR.
The data represent the mean ± SEM (#𝑝 < 0.05 and ##𝑝 < 0.005 versus the CHOW group; ∗𝑝 < 0.05 and ∗∗𝑝 < 0.005 versus the HFD group,
𝑛 = 5).
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may bemediated through food intake because decreased food
intake would be expected to significantly affect body weight,
which influences hepatic steatosis. In this study, however,
there was no difference in food intake-induced increase
of body weight between the FAVA-fed and non-FAVA-fed
groups (Figure 1(b)). This result suggests that FAVA directly
protected against obesity and hepatic steatosis independent
of food intake.
Obesity is most likely to cause hyperlipidemia, which
is considered the leading cardiovascular risk. The hallmark
of dyslipidemia in obesity is hypertriglyceridemia in combi-
nation with the preponderance of high LDL and low HDL
cholesterol [33]. This study shows that, in high-fat diet-fed
mice, FAVA supplementation significantly reduced serum
levels of cholesterol and the ratio of LDL cholesterol/total
cholesterol (Figures 3(c) and 3(d)). Furthermore, insulin
levels were increased in the HFD group and were decreased
significantly by FAVA supplementation (Figure 3(a)). In the
case of prediabetes, increases of blood glucose stimulate the
secretion of insulin and subsequently induce hyperinsuline-
mia to a normal blood glucose range. Hyperinsulinemia,
which is a biomarker of insulin resistance, is frequently
accompanied by obesity [34]. Leptin is a fat-derived hormone
that plays an important role in appetite control and energy
expenditure [35]. It has been reported that the concentration
of serum leptin is associated with general adiposity and
reflects the body fat content [36]. In this report, it was
demonstrated that FAVA treatment suppressed the plasma
leptin level inmice fedwithHFD (Figure 3(b)).Moreover, the
weight of adipose tissues strongly correlated with the plasma
leptin level. These results confirm that FAVA treatment
exerted an antiobesity effect in the diet-induced obesity
C57BL/6 mouse model.
PPAR-𝛾, a transcription factor predominantly expressed
in adipose tissue, plays an essential role in adipocyte dif-
ferentiation, lipid storage, and glucose homeostasis [37].
Additionally, adipogenesis is highly regulated by two primary
adipogenic transcription factors, PPAR-𝛾 and C/EBPs [38].
Among those factors, PPAR-𝛾 is well known as the key
regulator of adipogenic transcription [10]. PPAR-𝛾 is also
known to bind to the C/EBP-𝛼 promoter region that induces
the expression of C/EBP-𝛼 [39]. C/EBP-𝛼 is a promis-
ing candidate transcription factor for directly controlling
adipocyte differentiation [40]. We found that FAVA signifi-
cantly downregulated PPAR-𝛾 and C/EBP-𝛼mRNA levels in
the epididymal fat pad. This effect might be explained in two
ways: FAVA either inhibited PPAR-𝛾 and C/EBP-𝛼 or sup-
pressed the upstream molecules. Lipin-1 is also required in
adipocyte differentiation for the induction of the adipogenic
gene transcription [12]. We found that FAVA could inhibit
adipocyte differentiation through the suppression of lipin-1.
Acetoacetyl-CoA synthetase (AACS) can facilitate the
incorporation of ketones into lipogenesis [13]. Hasegawa et
al. [13] demonstrated that the AACS gene, which encodes
the ketone body-utilizing enzyme, is transcriptionally regu-
lated by SREBP-2 and the knockdown of SREBP-2 induced
downregulation of AACS and HMGCR gene expression.
Additionally, ketone body metabolism via AACS plays an
essential role in cholesterol homeostasis. In this study, we
showed that the treatment of mice with FAVA resulted in
a decrease of SREBP2, AACS, and HMGCR mRNA levels.
Therefore, our results suggest that FAVA improves obesity,
hyperlipidemia, and NAFLD and that FAVA treatment might
be a promising adjuvant therapy in the management of these
metabolic disorders.
5. Conclusions
FAVA had a marked inhibitory effect on the development
of obesity and NAFLD in a high-fat diet-induced obesity
mousemodel. Inhibiting transcription factors and adipocyte-
specific lipogenic genes and decreasing cholesterol synthesis
are two possible mechanisms for the antiobesity effect of
FAVA. This study suggests that FAVA might be a potential
dietary supplement for preventing obesity and NAFLD.
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